Selecta Biosciences Stock: Mind the Dilution

September 23. 2022. 6 mins read

Anyone who remembers the days of Flamel and Sky Pharma knows that the promise of nano drug delivery never really panned out for retail investors. These two firms promised to transform healthcare by using nanotechnology to deliver drugs more effectively. The technology moved on, while the supposed pioneers didn’t. The first nanotechnology-based cancer drugs to pass regulatory scrutiny were Doxil by Johnson and ABRAXANE by Bristol Myers Squibb, both of which were followed by a dozen more nano-enabled therapies for cancer alone. If you’re a firm that’s created a nanotechnology drug delivery platform, you’re not alone.

Click for company website

That brings us to Selecta Biosciences (SELB), a company we last looked at nine years ago prior to their initial public offering (IPO) which debuted in 2016 and raised $70 million. Since then, shares have lost 89% of their value giving the company a current market cap of around $229 million. That dismal performance doesn’t seem to match their consistent quarterly revenue growth.

Become a premium member and get access to hundreds of premium articles, reports and additional content.

Nanalyze Premium is your comprehensive guide to investing in disruptive technologies. Read by the top investment banks, management consultancies, VCs, and research houses. Trusted by over 100,000 institutional and retail investors. Covering disruptive technologies for over 18 years.